KLK3 and prostate carcinoma: For example, in prostate cancer cells, expression of KLK3 and KLK4 results in loss of E-cadherin and induction of expression of the mesenchymal marker vimentin, a hallmark of epithelial-to-mesenchymal transitions, which is a critical step for cancer metastasis [77].